Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PLX may be getting beat up but NEOP is still chuggin' along.
That was funny. First time I've laughed this morning. :)
This is not the first raid we have seen in our picks. I'm hanging tight. It won't be the last raid we'll see on our picks.
Congrats if your holding VRTX.
PLX and the markets....just a bad day in Flatbush.
Looks like a buying frenzy going on with DCTH.
OraSure Tech receives FDA approval for its OraQuick HCV rapid test using fingerstick whole blood (OSUR) 7.02 : Co announces its OraQuick HCV Rapid Antibody Test has now been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies with a fingerstick whole blood sample. The product received an initial approval for use in persons at risk for HCV infection with venous whole blood specimens in June 2010.
http://finance.yahoo.com/marketupdate/inplay
NEOP. I didn't know if anybody here had seen this report by Rodman & Renshaw. It shows info about other potential catalysts for Neoprobe in the near future.
http://rodmanrenshawreportfeb142011.blogspot.com/
OSUR-Orasure..$7.17 broke out of base today. Moving up nicely.
Is it possible ABT already knew this was coming?
DEPO-$9.08 premarket. FDA asks for evidence to demonstrate superiority of Gralise on improved safety.
A little before 3:00 pm a large block buy went through, around 500,000 shares.
Anadys Pharmaceuticals-ANDS..$1.43 moving up out of 1 1/2 month base. HOD $1.46
Not that I know of.
NLTX..$.68 hod
Anacor Pharmaceuticals-ANAC-$7.73.
$heff, what do you think about this thin float stock? GlaxoSmithKline owns more than 10% of this stock.
Medicis in $160M acne treatment deal with Anacor
Medicis could pay Anacor $160M plus royalties in deal to develop treatments for acne
Related Quotes
Symbol Price Change
ANAC 7.73 +0.64
On Thursday February 10, 2011, 12:06 pm EST
NEW YORK (AP) -- Medicis Pharmaceutical Corp. could pay Anacor Pharmaceuticals Inc. more than $160 million in return for the ability to research, develop and sell acne treatments.
Medicis will pay Anacor $7 million upfront and up to $153 million in research, development, regulatory and sales milestone payments. Anacor said Thursday it will also receive royalties on any products that reach the market. Anacor will be primarily responsible for discovering potential products and handling early research, and Medicis will handle all further development and commercialization. Anacor would receive royalties in the high single digits to low double digits under the deal.
Anacor, based in Palo Alto, Calif., develops drugs based on the element boron, and its product candidates include treatments for skin and fungal infections, psoriasis, atopic dermatitis, and onychomycosis, a fungal infection of the fingernails and toenails.
Link:http://finance.yahoo.com/news/Medicis-in-160M-acne-apf-1997346520.html?x=0&.v=1
CLSN
.Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox(R) HEAT Study to Treat Primary Liver Cancer
Related Quotes
Symbol Price Change
CLSN 2.63 0.00
{"s" : "clsn","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Celsion Corporation On Friday February 11, 2011, 8:00 am
COLUMBIA, MD--(Marketwire - 02/11/11) - Celsion Corporation (NASDAQ:CLSN - News), a leading oncology drug development company, today announced that after reviewing data from 482 randomized patients in its multinational, randomized, double-blind, placebo-controlled, pivotal Phase III clinical study of ThermoDox® in combination with radio frequency ablation for primary liver cancer (the HEAT study), the study's Data Monitoring Committee (DMC) has unanimously recommended that the trial continue enrollment. The HEAT study has enrolled over 86% of the 600 patients necessary to ensure that its primary end point, progression free survival, can be achieved with statistical significance.
"The DMC's recommendation to continue enrollment in the HEAT study marks an important milestone for Celsion and ThermoDox®, as it is its final scheduled evaluation ahead of enrollment completion," said Michael H. Tardugno, Celsion's President and Chief Executive Officer. "We remain optimistic and encouraged by this progress and by the potential for ThermoDox® to establish an effective standard of care for the enduring unmet need of patients with primary liver cancer."
The Company further announced that the DMC has maintained its recommendation to continue withholding enrollment of additional patients in Japan pending certain guidance from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. The recommendation follows a review of safety data from 18 Japanese patients enrolled in the study, when compared to patient data from the rest of the Phase III trial. As a part of its commitment to Japan's PMDA, the DMC independently assesses patients randomized at Japanese sites. As previously noted, overall toxicities for patients in the HEAT study are consistent with doxorubicin's labeled safety profile. Doxorubicin, the active therapeutic in ThermoDox®, is a widely used chemotherapeutic with a well known safety profile and approved globally for use, including Japan, in many cancer indications.
Regarding enrollment in Japan, Mr. Tardugno added: "We will continue working with our Japanese development partner and the DMC toward a timely resolution and the resumption of patient enrollment in Japan. While this process is ongoing, current enrollment in the HEAT study is continuing at 66 sites in ten other countries. We intend to move forward toward enrollment and study completion."
The DMC for the HEAT study is comprised of an independent group of medical and scientific experts with the responsibility for reviewing and evaluating patient safety and efficacy data from the Company's Phase III HEAT study. The DMC reviews study data at regular intervals with their primary responsibilities to ensure the safety of all patients enrolled in the trial, the quality of the data collected, and the continued scientific validity of the trial design. The trial design and statistical plan for the HEAT study also incorporates a pre-planned interim efficacy analysis by the DMC (after patient enrollment is complete and 190 progression-free survival events are realized in the study population) with the intent of evaluating safety and efficacy results to determine if there is overwhelming evidence of clinical benefit or a low probability of treatment success (a futility analysis) to continue, modify or terminate the trial.
Link:http://finance.yahoo.com/news/Data-Monitoring-Committee-iw-595000499.html?x=0&.v=1
Good, clarifying info. Thanks $heff.
Cytomedix Receives CE Mark for Angel and activAT
Press Release Source: Cytomedix, Inc. On Thursday February 10, 2011, 8:00 am
GAITHERSBURG, Md., Feb. 10, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company" or "Cytomedix") today announced that the Company has been issued a CE marking certification for its Angel(R) Whole Blood Separation System ("Angel") and its activAT(R) Autologous Thrombin Processing Kit ("activAT"). CE is a mandatory European marking for certain product groups to indicate conformity with the essential health and safety requirements set out in European Directives, and allows Cytomedix to freely sell and distribute its products throughout the 28 countries of the European Economic Area ("EEA").
Link:http://finance.yahoo.com/news/Cytomedix-Receives-CE-Mark-pz-3977844277.html?x=0&.v=1
Insider Holders*
Individual/Entity Most Recent Trans. Shares Owned as of Trans. Date
JORDEN DAVID EMERSON
Director Purchase
Feb 9, 2011 5,510,000
Feb 9, 2011
MASLAN ANDREW SCOTT
Officer Acquisition (Non Open Market)
Jan 18, 2011 57,940
Jan 18, 2011
ROSENDALE MARTIN P
Officer Acquisition (Non Open Market)
Jan 18, 2011 71,413
Jan 18, 2011
AIS-$1.81 breaking through resistance @ $1.80.
Protalix BioTherapeutics Presents Data on the Company's Fabry Program and Oral Enzyme Gaucher Program With Experts in the Field of Lysosomal Disorders
http://phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-newsArticle&ID=1517110&highlight=
NEOP approved for listing on the NYSE/AMEX on or about Feb.,10,2011
RNN-Rexahn Pharmaceutical $1.67 (hod $1.72) moving past resistance @ $1.65, next resistance $2.02.
PLX ($10.29) hod, rockin'.
MPG ($3.99) breaking out of base.
Thanks for the info $heff.
$heff do you have a new date for NLTX forward looking event? I see in the Ibox it's listed as Jan'11.
Bad day for CHTP-Chelsea Therapeutics-$4.69, down 24%. Interim results were not good.
$heff thanks for another home run. I appreciate your hard work and dedication for this board. You have assembled a great team here. Happy DEPO day to all.
F (Ford)100 dma $15.43 looks like a good place to buy IF it holds that support level.
Lyrica IS a controlled substance. Link to story:http://epilepsy.emedtv.com/lyrica/lyrica-abuse.html
An Overview of Lyrica Abuse
Lyrica® (pregabalin) is a prescription medication used to treat fibromyalgia and certain types of nerve pain and seizures. Studies have also shown that Lyrica is effective as an anxiety treatment -- though it is not approved for this use. Lyrica is a controlled substance. As with other controlled substances, there is the possibility of becoming addicted to Lyrica. Addiction or "dependence" is when a person feels like he or she needs to continue to take a medicine, even when no medical need is present.
$heff what are your thoughts on TSRX, Trius Therapeutics? There's a good article @ SA by Jason Napodano. Link to story:http://seekingalpha.com/article/248423-why-we-re-initiating-coverage-of-trius-therapeutics-with-an-outperform-rating?source=yahoo
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Torezolid phosphate (TR-701), an IV and orally administered second generation oxazolidinone, is currently in Phase 3 trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Link to company site:http://www.triusrx.com/trius-therapeutics-pipeline.php
TSRX has 54.37 mil cash, SO 23.58 mil, float 7.04 mil, shares short 8.92k.
Major Holders Get Major Holders for:
Breakdown
% of Shares Held by All Insider and 5% Owners: NaN
% of Shares Held by Institutional & Mutual Fund Owners: NaN
% of Float Held by Institutional & Mutual Fund Owners: NaN
Number of Institutions Holding Shares:
Major Direct Holders (Forms 3 & 4)
Holder Shares Reported
SOFINNOVA VENTURE PARTNERS VII L P 3,615,572 Aug 6, 2010
POWELL MICHAEL N/A Aug 6, 2010
KJELLSON NINA S N/A Aug 6, 2010
INTERWEST PARTNERS IX, LP 3,548,643 Aug 6, 2010
VERSANT VENTURE CAPITAL III, L.P. N/A Aug 6, 2010
AdChoices
Top Institutional Holders
Holder Shares % Out Value* Reported
WELLINGTON MANAGEMENT COMPANY, LLP 1,499,400 6.36 5,937,624 Sep 30, 2010
Ayer Capital Management, LP 672,196 2.85 2,661,896 Sep 30, 2010
SECTORAL ASSET MANAGEMENT, INC. 600,000 2.54 2,376,000 Sep 30, 2010
MILLENNIUM MANAGEMENT LLC 469,000 1.99 1,857,240 Sep 30, 2010
TIAA-CREF INVESTMENT MANAGEMENT, LLC 350,000 1.48 1,386,000 Sep 30, 2010
CITIGROUP INC. 274,173 1.16 1,085,725 Sep 30, 2010
FEDERATED INVESTORS, INC. 250,939 1.06 993,718 Sep 30, 2010
SUTTONBROOK CAPITAL MANAGEMENT LP 70,863 0.30 280,617 Sep 30, 2010
United Services Automobile Association 28,000 0.12 110,880 Sep 30, 2010
DEUTSCHE BANK AKTIENGESELLSCHAFT 200 0.00 792 Sep 30, 2010
Top Mutual Fund Holders
Holder Shares % Out Value* Reported
COLLEGE RETIREMENT EQUITIES FUND-STOCK ACCOUNT 350,000 1.48 1,386,000 Sep 30, 2010
FEDERATED KAUFMANN FUND 202,068 0.86 731,486 Oct 31, 2010
HARTFORD GLOBAL HEALTH FUND 141,800 0.60 513,316 Oct 31, 2010
USAA MUTUAL FD TR-SCIENCE & TECHNOLOGY FUND 28,000 0.12 101,360 Oct 31, 2010
FEDERATED KAUFMANN FUND II 6,700 0.03 26,532 Sep 30, 2010
FIDELITY NASDAQ COMPOSITE INDEX FUND 1,800 0.01 6,048 Nov 30, 2010
FIDELITY NASDAQ COMPOSITE INDEX TRACKING STOCK 938 0.00 3,151 Nov 30, 2010
Cabos_tacos have a great time. We just came back from a week at Punta Cana. Beats the heck out of the snow up here in R.I.
$heff did you exit your CLSN position? I think you bought around $2.38-$2.42 on 1/05/2011.
PLX, BPAX among some that ARE up.
PTX-Pernix Therapeutics ($9.41) with a high of $12.53. Head lice, treatment approved, is the second most communicable disease among schoolchildren after the common cold.
Link to story:
http://finance.yahoo.com/news/Pernix-Therapeutics-and-bw-2132568817.html?x=0&.v=1
DEPO hod $5.79
PLX($10.08) up through 20 dma.
Bear raid on DEPO?? Good opp to pick up cheap shares.
Yes, but on 1/11/2011 PLX was removed from the naked short list.
http://www.buyins.net/releases/index.php?sym=plx&id=140242